Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-13

Clinical Trial Update: Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib in advanced or recurrent malignant pleural mesothelioma has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2013-12-13